Back to Journals » Patient Related Outcome Measures » Volume 6

Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation

Authors Maggiolo F, Colombo G, Di Matteo S, Bruno GM, Astuti N, Di Filippo E, Masini G, Bernardini C

Received 5 March 2014

Accepted for publication 8 October 2014

Published 17 February 2015 Volume 2015:6 Pages 53—60

DOI https://doi.org/10.2147/PROM.S63586

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Robert Howland

Franco Maggiolo,1 Giorgio L Colombo,2,3 Sergio Di Matteo,3 Giacomo M Bruno,3 Noemi Astuti,1 Elisa Di Filippo,1 Giulia Masini,1 Claudia Bernardini1

1Division of Infectious Diseases, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; 2University of Pavia, Department of Drug Sciences, Pavia, Italy; 3SAVE Studi Analisi Valutazioni Economiche, Milan, Italy

Objectives: Costs may play a role in deciding how and when to start highly active antiretroviral therapy (HAART) in a naïve patient. The aim of the present study was to assess the cost- effectiveness of treatment with HAART in a large clinical cohort of naïve adults to determine the potential role of single-tablet regimens in the management of patients with human immunodeficiency virus (HIV). An incremental cost-effectiveness ratio analysis was performed, including a quality-adjusted life year approach.
Results: In total, 741 patients (females comprising 25.5%) were retrospectively included. The mean age was 39 years, the mean CD4 cell count was 266 cells/µL, and the mean viral load was 192,821 copies/mL. The most commonly used backbone was tenofovir + emtricitabine (77.6%); zidovudine + lamivudine was used in 10%, lamivudine + abacavir in 3%, and other nucleoside reverse transcriptase inhibitor (NRTI) or NRTI-free regimens in 9.4% of patients. NNRTIs were used in 52.8% of cases, boosted protease inhibitors in 44.1%, and unboosted protease inhibitors and integrase inhibitors in 0.7% and 2.4%, respectively. Starting therapy at CD4 >500 cells/µL and CD4 351–500 cells/µL rather than at <201 cells/µL was the more cost-effective approach. The same consideration was not true comparing current indications with the possibility to start HAART at any CD4 value (eg, >500 cells per µL); in this case, the incremental cost-effectiveness ratio value was €199,130 per quality-adjusted life year gained, a higher value than the one suggested in guidelines. The single-tablet regimen (STR) invariably dominated any other therapeutic approach. Sensitivity analysis was performed, and starting right away with an STR was cost-effective even when compared with therapeutic strategies contemplating STR as simplification.
Conclusion: By integrating clinical data with economic variables, our study offers an estimate of the cost-effectiveness of the various first-line treatment strategies for patients infected with HIV and provides significant evidence to be used in future prospective pharmacoeconomic evaluations.

Keywords: cost-effectiveness, quality-adjusted life years, highly active antiretroviral therapy, single-tablet regimen


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers

Colombo GL, Cammà C, Attili AF, Ganga R, Gaeta GB, Brancaccio G, Franzini JM, Volpe M, Turchetti G

Therapeutics and Clinical Risk Management 2015, 11:1603-1612

Published Date: 19 October 2015

Economic and outcomes consequences of TachoSil®: a systematic review

Colombo GL, Bettoni D, Di Matteo S, Grumi C, Molon C, Spinelli D, Mauro G, Tarozzo A, Bruno GM

Vascular Health and Risk Management 2014, 10:569-576

Published Date: 10 September 2014

Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines

Colombo GL, Matteo SD, Antinori A, Medaglia M, Murachelli S, Rizzardini G

ClinicoEconomics and Outcomes Research 2013, 5:489-496

Published Date: 3 October 2013

A cost-of-illness study of spina bifida in Italy

Colombo GL, Di Matteo S, Vinci M, Gatti C, Pascali MP, De Gennaro M, Macrellino E, Mosiello G, Redaelli T, Schioppa F, Dieci C

ClinicoEconomics and Outcomes Research 2013, 5:309-316

Published Date: 2 July 2013

Cost and appropriateness of treating asthma with fixed-combination drugs in local health care units in Italy

Ruggeri I, Bragato D, Colombo GL, Valla E, Di Matteo S

ClinicoEconomics and Outcomes Research 2012, 4:375-382

Published Date: 5 December 2012

Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy

Rizzardini G, Bonfanti P, Carenzi L, Coen M, Orlando G, Di Matteo S, Colombo GL

Therapeutics and Clinical Risk Management 2012, 8:377-384

Published Date: 17 September 2012

Antidiabetic therapy in real practice: indicators for adherence and treatment cost

Colombo GL, Rossi E, De Rosa M, Benedetto D, Gaddi AV

Patient Preference and Adherence 2012, 6:653-661

Published Date: 14 September 2012

Burden of Crohn’s disease: economics and quality of life aspects in Italy

Benedini V, Caporaso N, Corazza GR, Rossi Z, Fornaciari G, Cottone M, Frosini G, Caruggi M, Ottolini C, Colombo GL

ClinicoEconomics and Outcomes Research 2012, 4:209-218

Published Date: 24 July 2012

Cost-effectiveness analysis of initial HIV treatment under Italian guidelines

Colombo GL, Colangeli V, Di Biagio A, Di Matteo S, Viscoli C, Viale P

ClinicoEconomics and Outcomes Research 2011, 3:197-205

Published Date: 31 October 2011

Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A

Giorgio L Colombo, Sergio Di Matteo, Maria Elisa Mancuso, et al

ClinicoEconomics and Outcomes Research 2011, 3:55-61

Published Date: 14 March 2011

A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy

Giorgio L Colombo, Giovanni B Gaeta, Mauro Viganò, et al

ClinicoEconomics and Outcomes Research 2011, 3:37-46

Published Date: 15 February 2011

A cost–utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy

Giorgio L Colombo, Sergio Di Matteo, Ketty Peris, Maria Concetta Fargnoli, et al.

ClinicoEconomics and Outcomes Research 2009, 1:53-59

Published Date: 15 October 2009

Assessment of acceptability and ease of use of atovaquone/proguanil medication in subjects undergoing malaria prophylaxis

V Nicosia, Giorgio Colombo, M Consentino, S Di Matteo, F Mika, et al

Therapeutics and Clinical Risk Management 2008, 4:1105-1110

Published Date: 10 October 2008

Moderate and severe plaque psoriasis: cost-of-illness study in Italy

GL Colombo, GF Altomare, K Peris, P Martini, G Quarta

Therapeutics and Clinical Risk Management 2008, 4:559-568

Published Date: 11 April 2008

Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy

Giorgio L Colombo, Mauro Caruggi, Chiara Ottolini, Aldo P Maggioni

Vascular Health and Risk Management 2008, 4:223-234

Published Date: 8 February 2008

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Effects of Arthro-7® in relieving symptoms of osteoarthritis with mild to moderate arthralgia [Corrigendum]

Xie Q, Zhou T, Yen L, Shariff M, Nguyen T, Kami K, Gu P, Liang L, Rao J, Shi R

Nutrition and Dietary Supplements 2013, 5:7-8

Published Date: 16 May 2013

Successful two-stage revision of a KineSpring® joint unloading implant: a case study

Bowditch M, Miller LE, Block JE

International Medical Case Reports Journal 2012, 5:91-95

Published Date: 12 December 2012

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010